$0.72
4.82%
Nasdaq, Apr 21, 08:48 pm CET
ISIN
US67577R1023
Symbol
IRD
Sector
Industry

Ocuphire Pharma Inc Stock price

$0.76
-0.18 19.30% 1M
-0.51 40.17% 6M
-0.43 36.14% YTD
-0.98 56.33% 1Y
-1.89 71.32% 3Y
-6.84 90.00% 5Y
-356.26 99.79% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
+0.02 3.37%
ISIN
US67577R1023
Symbol
IRD
Sector
Industry

Key metrics

Market capitalization $35.86m
Enterprise Value $24.38m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.22
P/S ratio (TTM) P/S ratio 3.26
P/B ratio (TTM) P/B ratio 3.57
Revenue growth (TTM) Revenue growth -42.30%
Revenue (TTM) Revenue $10.99m
EBIT (operating result TTM) EBIT $-34.07m
Free Cash Flow (TTM) Free Cash Flow $-25.58m
Cash position $30.32m
EPS (TTM) EPS $-1.99
P/E forward negative
P/S forward 2.70
EV/Sales forward 1.84
Short interest 2.05%
Show more

Is Ocuphire Pharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Ocuphire Pharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Ocuphire Pharma Inc forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a Ocuphire Pharma Inc forecast:

Buy
100%

Financial data from Ocuphire Pharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
11 11
42% 42%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 18 18
52% 52%
166%
- Research and Development Expense 27 27
52% 52%
244%
-34 -34
223% 223%
-310%
- Depreciation and Amortization 0.01 0.01
0% 0%
0%
EBIT (Operating Income) EBIT -34 -34
223% 223%
-310%
Net Profit -58 -58
476% 476%
-523%

In millions USD.

Don't miss a Thing! We will send you all news about Ocuphire Pharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ocuphire Pharma Inc Stock News

Neutral
GlobeNewsWire
10 days ago
Board Timed Highly Dilutive Financing to Close on the Record Date for the Annual Meeting, Tilting the Vote and Forcing the Withdrawal of the Restore Value Slate
Neutral
GlobeNewsWire
13 days ago
First pediatric patient shows encouraging early safety profile and meaningful improvement in visual function at one month A second pediatric patient was recently dosed, and the pediatric cohort is expected to complete enrollment in Q2 2025; initial data from all three patients anticipated in Q3 2025 FDA Type D meeting provided clarity on next steps for a registrational trial design to support B...
Neutral
GlobeNewsWire
19 days ago
RESEARCH TRIANGLE PARK, N.C., April 02, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and therapies for other ophthalmic disorders, today announced that George Magrath, M.D.
More Ocuphire Pharma Inc News

Company Profile

Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.

Head office United States
CEO George Magrath
Employees 18
Founded 2018
Website opusgtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today